3,511 results found

Further to our June 1, 2020 update, regulations amending the coming into force date of the Regulations Amending the Patented Medicines Regulations

On Friday, September 8, Yasir Naqvi, Attorney General, Charles Sousa, Minister of Finance and Eric Hoskins, Minister of Health and Long-Term Care, announced a comprehensive framework outlining...

During the past couple of days, the Government of Ontario has announced a long-awaited decision regarding the anticipated expansion of the market for the legal use of cannabis.

As of October 17, 2019, the production and sale of edible cannabis, cannabis extracts and cannabis topicals became legal.

On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.

On November 20, 2024, the Federal Court dismissed EMD Serono (Serono)'s judicial review of the Minister of Health's decision to list Canadian Patent No. 3,087,419 (419 Patent)...

The Supreme Court has dismissed Teva's application for leave to appeal. The Patented Medicine Prices Review Board (the "Board") commenced this proceeding against Sandoz by Notice of Application.

This article provides an update to our series on the use of real-world data ("RWD") and real-world evidence ("RWE"). The Pharmaceutical Advertising Advisory Board (PAAB) has published revisions...

Plaintiffs usually start lawsuits by serving the defendant personally with a statement of claim. While personal service is the "gold standard," Ontario's Rules of Civil Procedure permit alternative...

While much of the data on food labels is incomprehensible to the average consumer, at least "best before dates" and "packaging dates" are easy to understand.

With the legalization of marijuana appearing to be more like an inevitability than a possibility, the options for consuming marijuana continue to expand.

Earlier this month a proposed class action was filed in Montreal by the Consumer Law Group alleging that Merck, Shering-Plough and Daiichi Sankyo provided inadequate warnings...

Staff of the securities regulatory authorities in Ontario, British Columbia, Québec, New Brunswick, Saskatchewan, Manitoba and Nova Scotia (collectively, Staff) has released CSA Multilateral Staff Notice 51-359 ‒

In the wake of federal plans to legalize recreational cannabis use, the Western Provinces announced licensing schemes for private sale.

As the government prepares for legalization of recreational marijuana this summer, Canada's cannabis producers and distributors are bracing themselves for a period of consolidation leading up to and following legalization.

As demand for organic and natural food continues to increase, food industry leaders look for new ways to attract health conscious consumers.

The case for taking a U.S. cannabis company public in Canada is simple: Canada is the world's top source for public venture and growth capital.

A surprising number of pharmacies and pharmacists are fraudulently overbilling the Ontario Drug Benefit (ODB) Program for millions of dollars and they are largely getting away with it.